Real-world impact of Omnipod® 5 in
type 2 diabetes

Hosted by Insulet employee, Nancy Hanna

In this special ADA 2025 edition of Beyond the Bolus, host Nancy sits down with Kellee Miller and Jennifer Boyd from Insulet’s Medical Affairs team to discuss groundbreaking data on the Omnipod 5 Automated Insulin Delivery System in people with type 2 diabetes. From real-world evidence across 23,000+ users to insights on insulin dosing, quality of life, and optimized settings, this episode dives deep into how Omnipod 5 is transforming diabetes care. Whether you're a prescriber, educator, or caring for someone living with diabetes, this conversation offers valuable takeaways on the future of AID technology.

Time stamps

01:13 – SECURE-T2D study refresh
02:52 – Why real-world evidence enables unbiased, large-scale real-world insights
04:10 – Challenging carb counting norms
08:50 – What predicts success with Omnipod 5?

 

The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information.